DIACC3010, formerly M2698, is a Phase II-ready dual PAM inhibitor with rare brain-penetration properties

Merck to become a shareholder of Diaccurate, remains fully committed to the success of the drug candidate

Diaccurate to start exploratory Phase II programs in incurable solid tumors and lymphomas by H2 2022

Acquisition broadens Diaccurate’s sole-in-class oncology and immunotherapy product pipeline and transforms it into a clinical−stage biotech mpany